TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen

Completed 215 enrolled Centers for Disease Control and Prevention US Department of Veterans Affairs · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary objective: To determine the rate of confirmed treatment failure and relapse with an intermittent rifabutin-based regimen for the treatment of isoniazid and rifamycin-susceptible HIV-related tuberculosis (TB).

Timeline

Start: 1999-02
Primary completion: —
Completion: 2003-02

Publications

Background Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T; Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005 May 15;40(10):1481-91. doi: 10.1086/429321. Epub 2005 Apr 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rifabutin	Small molecule	—	—

TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen

Summary

Timeline

Publications

Drugs

Indications